简短报告：注射吸毒风险行为与免疫激活标志物之间的关系
Brief Report: The Relationship Between Injection Drug Use Risk Behaviors and Markers of Immune Activation.
作者信息
Deren Sherry, Cleland Charles M, Lee Haekyung, Mehandru Saurabh, Markowitz Martin
机构信息
*Center for Drug Use and HIV Research, Rory Meyers College of Nursing, New York University, New York, NY; †Division of Gastroenterology, Department of Medicine, Mount Sinai School of Medicine, New York, NY; and ‡Aaron Diamond AIDS Research Center and The Rockefeller University, New York, NY.
出版信息
J Acquir Immune Defic Syndr. 2017 May 1;75(1):e8-e12. doi: 10.1097/QAI.0000000000001270.
Abstract
High levels of immune activation are reported for people who inject drugs. Studies of the relationship between injection behaviors and immune activation have yielded mixed results, in part due to lack of control for hepatitis C virus in analyses. This study, of 48 HIV-seronegative people who inject drugs, examines this relationship controlling for hepatitis C virus viremia. Frequency of injection was positively related to markers of immune activation (soluble CD14, %CD8CD38HLADR T cells), as was duration of injection (high-specificity C-reactive protein and D-dimer). Sharing injection equipment was not related to markers studied. Findings suggest that efforts to encourage injection cessation or reduction in frequency can have positive health benefits through reducing immune activation.
摘要
据报道，注射毒品者的免疫激活水平较高。对注射行为与免疫激活之间关系的研究结果不一，部分原因是分析中未对丙型肝炎病毒进行控制。这项针对48名注射毒品的HIV血清阴性者的研究，在控制丙型肝炎病毒血症的情况下考察了这种关系。注射频率与免疫激活标志物（可溶性CD14、%CD8CD38HLADR T细胞）呈正相关，注射持续时间（高特异性C反应蛋白和D-二聚体）也与之呈正相关。共用注射器具与所研究的标志物无关。研究结果表明，鼓励停止注射或减少注射频率的努力可通过降低免疫激活而带来积极的健康益处。
相似文献
1
Brief Report: The Relationship Between Injection Drug Use Risk Behaviors and Markers of Immune Activation.
J Acquir Immune Defic Syndr. 2017 May 1;75(1):e8-e12. doi: 10.1097/QAI.0000000000001270.
2
Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217.
J Acquir Immune Defic Syndr. 2017 May 1;75(1):137-141. doi: 10.1097/QAI.0000000000001320.
3
Immune Activation by Mycobacterium tuberculosis in HIV-Infected and -Uninfected Subjects.
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):103-111. doi: 10.1097/QAI.0000000000001157.
4
Asymptomatic anorectal Chlamydia trachomatis and Neisseria gonorrhoeae infections are associated with systemic CD8+ T-cell activation.
AIDS. 2017 Sep 24;31(15):2069-2076. doi: 10.1097/QAD.0000000000001580.
5
Drug-resistant virus has reduced ability to induce immune activation.
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):e60-3. doi: 10.1097/QAI.0b013e31827171d7.
6
Chronic Hepatitis C Virus Infection and the Proinflammatory Effects of Injection Drug Use.
J Infect Dis. 2016 Nov 1;214(9):1376-1382. doi: 10.1093/infdis/jiw373. Epub 2016 Aug 11.
7
Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.
AIDS Res Hum Retroviruses. 2017 Feb;33(2):133-142. doi: 10.1089/AID.2016.0108. Epub 2016 Oct 18.
8
Expression and Function of NKG2D Is Impaired in CD8+ T Cells of Chronically HIV-1-Infected Patients Without ART.
J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):347-56. doi: 10.1097/QAI.0000000000000792.
9
Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
J Med Virol. 2016 Aug;88(8):1347-56. doi: 10.1002/jmv.24475. Epub 2016 Jan 20.
10
Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Oct 1;16(2):83-92. doi: 10.1097/00042560-199710010-00003.
引用本文的文献
1
Factors mediating and associated with immunological response in women living with HIV in Sweden: A nationwide register-based study.
HIV Med. 2025 Jun 12;26(8):1311-6. doi: 10.1111/hiv.70059.
2
Adverse childhood experiences, resilience, and syringe services program attendance among persons who inject drugs in Northeast Georgia, USA: A mediation analysis.
Drug Alcohol Depend Rep. 2024 Dec 10;14:100309. doi: 10.1016/j.dadr.2024.100309. eCollection 2025 Mar.
3
Relationships Among COVID-19-Related Service Uptake, HIV Status, Drug Use, and COVID-19 Antibody Status Among HIV Testing Intervention Participants in KwaZulu-Natal, South Africa.
Int J Environ Res Public Health. 2024 Oct 25;21(11):1411. doi: 10.3390/ijerph21111411.
4
Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy.
Front Immunol. 2024 Feb 14;15:1352440. doi: 10.3389/fimmu.2024.1352440. eCollection 2024.
5
HIV-1 latency reversal agent boosting is not limited by opioid use.
medRxiv. 2024 Jun 4:2023.05.26.23290576. doi: 10.1101/2023.05.26.23290576.
6
Employing Respondent Driven Sampling (RDS) to recruit people who inject drugs (PWID) and other hard-to-reach populations during COVID-19: Lessons learned.
Front Psychiatry. 2022 Oct 3;13:990055. doi: 10.3389/fpsyt.2022.990055. eCollection 2022.
7
Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial.
Viruses. 2021 Jul 13;13(7):1351. doi: 10.3390/v13071351.
8
Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review.
Curr HIV/AIDS Rep. 2020 Aug;17(4):354-372. doi: 10.1007/s11904-020-00498-y.
9
DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty.
Nat Commun. 2017 Dec 21;8(1):2243. doi: 10.1038/s41467-017-02326-1.
10
Influence of Injection Drug Use-Related HIV Acquisition on CD4 Response to First Antiretroviral Therapy Regimen Among Virally Suppressed Individuals.
J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):317-324. doi: 10.1097/QAI.0000000000001607.
本文引用的文献
1
The Immune System of HIV-Exposed Uninfected Infants.
Front Immunol. 2016 Sep 28;7:383. doi: 10.3389/fimmu.2016.00383. eCollection 2016.
2
Chronic Hepatitis C Virus Infection and the Proinflammatory Effects of Injection Drug Use.
J Infect Dis. 2016 Nov 1;214(9):1376-1382. doi: 10.1093/infdis/jiw373. Epub 2016 Aug 11.
3
Challenges in Recruiting People Who Use Drugs for HIV-Related Biomedical Research: Perspectives from the Field.
AIDS Patient Care STDS. 2016 Aug;30(8):379-84. doi: 10.1089/apc.2016.0135.
4
Behavioural, Mucosal and Systemic Immune Parameters in HIV-infected and Uninfected Injection Drug Users.
J Addict Res Ther. 2015;6(4):1-8. doi: 10.4172/2155-6105.1000257.
5
Immune activation and immune aging in HIV infection.
Curr Opin HIV AIDS. 2016 Mar;11(2):242-9. doi: 10.1097/COH.0000000000000240.
6
Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs.
Med Microbiol Immunol. 2016 Jun;205(3):231-9. doi: 10.1007/s00430-015-0444-8. Epub 2015 Dec 22.
7
Paradoxical changes in innate immunity in aging: recent progress and new directions.
J Leukoc Biol. 2015 Dec;98(6):937-43. doi: 10.1189/jlb.5MR0315-104R. Epub 2015 Jul 17.
8
Inflammation Partially Mediates the Association of Multimorbidity and Functional Limitations in a National Sample of Middle-Aged and Older Adults: The MIDUS Study.
J Aging Health. 2015 Aug;27(5):843-63. doi: 10.1177/0898264315569453. Epub 2015 Feb 2.
9
Innate activation of MDC and NK cells in high-risk HIV-1-exposed seronegative IV-drug users who share needles when compared with low-risk nonsharing IV-drug user controls.
J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):264-73. doi: 10.1097/QAI.0000000000000470.
10
The role of inflammation in age-related disease.
Aging (Albany NY). 2013 Jan;5(1):84-93. doi: 10.18632/aging.100531.
Zotero 插件